Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001144204-10-015179)

Filing Details

Accession Number:: 0001144204-10-015179
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-23 13:00:00
Reporting Period:: 2010-03-22

Filing Date:: 2010-03-23
Accepted Time:: 2010-03-23 16:05:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1318641	Cleveland Biolabs Inc	CBLI	Services-Commercial Physical & Biological Research (8731)	200077155

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1369806	Michael Fonstein	73 High Street Buffalo NY 14203	Ceo, President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-03-22	300	$3.56	1,275,900	No	4	S	Direct
Common Stock	Disposition	2010-03-22	666	$3.55	1,275,234	No	4	S	Direct
Common Stock	Disposition	2010-03-22	300	$3.59	1,274,934	No	4	S	Direct
Common Stock	Disposition	2010-03-22	2,334	$3.58	1,272,600	No	4	S	Direct
Common Stock	Disposition	2010-03-22	1,400	$3.57	1,271,200	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Employee Stock Options (Right to Buy)	$8.36	2007-04-06	2017-04-05	37,500	37,500	Direct
Common Stock	Employee Stock Options (Right to Buy)	$4.00	2008-02-04	2018-02-03	137,250	174,750	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2017-04-05	37,500	37,500	Direct
2018-02-03	137,250	174,750	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.4% of the reporting person's 1,311,200 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 4.6% of the reporting person's shares held prior to adoption of the plan.